|
View Agenda and
Faculty | Register | Exit
Who Should Participate
This
activity is intended for internal medicine physicians and other healthcare
professionals interested in the diagnosis and treatment of fibromyalgia (FM).
Overview
This
activity will be designed for clinicians who encounter patients with
fibromyalgia and will provide updates and offer solutions to the most
common clinical challenges surrounding fibromyalgia. Recognized experts
will facilitate the activity, which will focus on practical information
surrounding differential diagnosis, new insights regarding shared
pathophysiology with other chronic pain conditions, and step-wise
treatment plans. Presentations will highlight distinct roles each
clinician group contributes to the management of fibromyalgia and will
demonstrate clinical decision-making with case scenarios. Participants
will also benefit from a question and answer session.
Learning
Objectives
The
primary goal for the proposed initiative is to increase providers’
ability to diagnose and treat FM. At the end of this program, the
participant should
be able to
|
|
1. |
Differentiate
fibromyalgia from comorbidities and conditions with similar
symptoms, such as myofascial pain syndrome or polymyalgia rheumatica,
using
American
College
of Rheumatology (ACR) criteria. |
|
2. |
Evaluate
the use of pregabalin, tricyclic compounds, dual reuptake
inhibitors, analgesics, antidepressants, and antiepileptics in the
treatment of fibromyalgia and prescribe appropriate pharmacological
treatments for fibromyalgia based on the latest clinical trial data
and practice guidelines. |
|
3. |
Apply
multidisciplinary approaches that incorporate two or more strategies
to decrease pain and improve function in fibromyalgia. |
|
4. |
Formulate
an approach to discussing the likely course of fibromyalgia with
patients and their families, including the likelihood of flare-ups
despite treatment, the need to monitor and report treatment side
effects, and the importance of long-term treatment compliance. |
Accreditation
Statement
This
activity has been planned and implemented in accordance with the
Essential Areas and policies of the Accreditation Council for Continuing
Medical Education (ACCME) through the joint sponsorship of the
University
of
California, Irvine School of Medicine (UCI) and CME Enterprise. The
University
of
California, Irvine School of Medicine is accredited by the ACCME to provide
continuing medical education for physicians.
Credit Designation
Statement
The
University
of
California, Irvine School of Medicine designates this educational activity for a
maximum of 1.0 AMA PRA Category 1
Credits™.
Physicians should only claim credit commensurate with the extent of
their participation in the activity.
General
Disclosure Statement
It
is the policy of the
University
of California, Irvine School of Medicine and the
University
of
California CME Consortium
to ensure balance, independence, objectivity, and scientific rigor in
all CME activities. Full disclosure of conflict resolution will be
made in writing via handout materials or syllabus.
This
activity is in compliance with California Assembly Bill 1195, which
requires continuing medical education activities with patient care
components to include curriculum in the subjects of cultural and
linguistic competency. For specific information regarding Bill 1195 and
definitions of cultural and linguistic competency, please visit the CME
Web site at www.cme.uci.edu.
| Supported by an educational grant from
Eli Lilly and Company
|
|
 |
|
 |
The
University
of
California,
Irvine School of Medicine and
CME Enterprise fully comply with
the legal requirements of the Americans with
Disabilities Act and the rules and regulations thereof. If any
participant who is planning to attend this educational activity has
an on-site need,
please call Bill Heckaman at 317.208.3615 by May 7,
2008, in order to receive service. |
[
Top ]
|
